Merck & Company Stock Price, News & Analysis (NYSE:MRK)

$55.20 0.03 (0.05 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$55.20
Today's Range$55.43 - $54.75
52-Week Range$54.40 - $66.80
Volume9.87 million shs
Average Volume14.90 million shs
Market Capitalization$150.38892 billion
P/E Ratio14.19
Dividend Yield3.41%
Beta0.78

About Merck & Company (NYSE:MRK)

Merck & Company logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Sector: Medical
  • Symbol: NYSE:MRK
  • CUSIP: 58933Y10
  • Web: www.merck.com
Debt:
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 1.43%
  • Quick Ratio: 1.16%
Price-To-Earnings:
  • Trailing P/E Ratio: 14.19
  • Forward P/E Ratio: 13.97
  • P/E Growth: 2.38
Sales & Book Value:
  • Annual Sales: $39.807 billion
  • Price / Sales: 3.78
  • Cash Flow: $5.80 per share
  • Price / Cash: 9.52
  • Book Value: $14.62 per share
  • Price / Book: 3.78
Dividend:
  • Annual Dividend: $1.88
  • Dividend Yield: 3.4%
Profitability:
  • Trailing EPS: $1.67
  • Net Income: $3.92 billion
  • Net Margins: 11.60%
  • Return on Equity: 27.08%
  • Return on Assets: 11.41%
Misc:
  • Employees: 68,000
  • Outstanding Shares: 2,724,440,000
 

Frequently Asked Questions for Merck & Company (NYSE:MRK)

What is Merck & Company's stock symbol?

Merck & Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Company pay dividends? What is the dividend yield for Merck & Company?

Merck & Company declared a quarterly dividend on Tuesday, July 25th. Investors of record on Friday, September 15th will be paid a dividend of $0.47 per share on Friday, October 6th. This represents a $1.88 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Thursday, September 14th. View Merck & Company's Dividend History.

How were Merck & Company's earnings last quarter?

Merck & Company, Inc. (NYSE:MRK) announced its earnings results on Friday, October, 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.03 by $0.08. The firm earned $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. Merck & Company had a net margin of 11.60% and a return on equity of 27.08%. The firm's revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.07 earnings per share. View Merck & Company's Earnings History.

When will Merck & Company make its next earnings announcement?

Merck & Company is scheduled to release their next quarterly earnings announcement on Friday, February, 2nd 2018. View Earnings Estimates for Merck & Company.

What guidance has Merck & Company issued on next quarter's earnings?

Merck & Company updated its FY17 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $3.91-3.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.88. The company issued revenue guidance of $40.0-40.5 billion, compared to the consensus revenue estimate of $40.34 billion.

Where is Merck & Company's stock going? Where will Merck & Company's stock price be in 2017?

17 analysts have issued 1 year price targets for Merck & Company's shares. Their predictions range from $48.00 to $74.00. On average, they expect Merck & Company's share price to reach $66.64 in the next year. View Analyst Ratings for Merck & Company.

What are Wall Street analysts saying about Merck & Company stock?

Here are some recent quotes from research analysts about Merck & Company stock:

  • 1. According to Zacks Investment Research, "Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to sales. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced in the first half with several key regulatory approvals. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern. Merck’s shares underperformed the industry this year so far. Estimates have declined slightly ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters." (10/17/2017)
  • 2. BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
  • 3. Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)

Who are some of Merck & Company's key competitors?

Who are Merck & Company's key executives?

Merck & Company's management team includes the folowing people:

  • Kenneth C. Frazier, Chairman of the Board, President, Chief Executive Officer (Age 62)
  • Robert M. Davis, Chief Financial Officer, Executive Vice President (Age 50)
  • Michael J. Holston, Executive Vice President, General Counsel (Age 54)
  • Mirian M. Graddick-Weir, Executive Vice President - Human Resources (Age 62)
  • Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division (Age 57)
  • Richard R. DeLuca Jr., Executive Vice President, President - Merck Animal Health (Age 54)
  • Julie Louise Gerberding M.D., Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health (Age 61)
  • Roger M. Perlmutter M.D. Ph.D., Executive Vice President, President - Merck Research Laboratories (Age 65)
  • Adam H. Schechter, Executive Vice President, President - Global Human Health (Age 52)
  • Rita A. Karachun, Senior Vice President Finance - Global Controller (Age 53)

Who owns Merck & Company stock?

Merck & Company's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.42%), Ameriprise Financial Inc. (0.86%), Boston Partners (0.69%), Legal & General Group Plc (0.54%), Macquarie Group Ltd. (0.41%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Merck & Company stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Company.

Who sold Merck & Company stock? Who is selling Merck & Company stock?

Merck & Company's stock was sold by a variety of institutional investors in the last quarter, including Sanders Capital LLC, Bank of New York Mellon Corp, Macquarie Group Ltd., Principal Financial Group Inc., Schroder Investment Management Group, State of Wisconsin Investment Board, Brandes Investment Partners LP and APG Asset Management N.V.. Company insiders that have sold Merck & Company company stock in the last year include Adam H Schechter, C Robert Kidder, Michael J Holston, Patricia F Russo, Thomas H Glocer, Thomas R Cech and Wendell P Weeks. View Insider Buying and Selling for Merck & Company.

Who bought Merck & Company stock? Who is buying Merck & Company stock?

Merck & Company's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Capital International Investors, Stifel Financial Corp, Amundi Pioneer Asset Management Inc., Alyeska Investment Group L.P., Ameriprise Financial Inc., American Century Companies Inc. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Merck & Company.

How do I buy Merck & Company stock?

Shares of Merck & Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Company's stock price today?

One share of Merck & Company stock can currently be purchased for approximately $55.20.

How big of a company is Merck & Company?

Merck & Company has a market capitalization of $150.38892 billion and generates $39.807 billion in revenue each year. The company earns $3.92 billion in net income (profit) each year or $1.67 on an earnings per share basis. Merck & Company employs 68,000 workers across the globe.

How can I contact Merck & Company?

Merck & Company's mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000.


MarketBeat Community Rating for Merck & Company (NYSE MRK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  573 (Vote Outperform)
Underperform Votes:  578 (Vote Underperform)
Total Votes:  1,151
MarketBeat's community ratings are surveys of what our community members think about Merck & Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Merck & Company (NYSE:MRK)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $66.64 (20.73% upside)

Consensus Price Target History for Merck & Company (NYSE:MRK)

Price Target History for Merck & Company (NYSE:MRK)

Analysts' Ratings History for Merck & Company (NYSE:MRK)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Sanford C. BernsteinReiterated RatingBuy$64.00N/AView Rating Details
11/3/2017Cowen and CompanyReiterated RatingHold$70.00N/AView Rating Details
11/1/2017Berenberg BankReiterated RatingHoldN/AView Rating Details
11/1/2017Jefferies Group LLCDowngradeHold -> UnderperformN/AView Rating Details
10/30/2017BMO Capital MarketsSet Price TargetBuy$70.00 -> $68.00N/AView Rating Details
10/30/2017Leerink SwannLower Price TargetMarket Perform$70.00 -> $69.00N/AView Rating Details
10/30/2017Citigroup Inc.UpgradeBuyN/AView Rating Details
10/29/2017J P Morgan Chase & CoSet Price TargetBuy$70.00N/AView Rating Details
10/30/2017Morgan StanleyDowngradeOverweight -> Equal Weight$56.00N/AView Rating Details
10/30/2017SunTrust Banks, Inc.DowngradeBuy -> HoldN/AView Rating Details
10/30/2017Barclays PLCDowngradeOverweight -> Equal Weight$72.00 -> $62.00N/AView Rating Details
9/5/2017Credit Suisse GroupReiterated RatingOutperform$75.00 -> $74.00LowView Rating Details
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$70.00LowView Rating Details
7/27/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $74.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$64.00 -> $66.00LowView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00N/AView Rating Details
10/13/2016Bank of America CorporationUpgradeNeutral -> Buy$57.00 -> $70.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Merck & Company (NYSE:MRK)

Earnings by Quarter for Merck & Company (NYSE:MRK)

Earnings History by Quarter for Merck & Company (NYSE MRK)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2018$0.94N/AView Earnings Details
10/27/2017Q3 2017$1.03$1.11$10.54 billion$10.33 billionViewN/AView Earnings Details
7/28/2017Q2 17$0.87$1.01$9.75 billion$9.93 billionViewN/AView Earnings Details
5/2/2017Q1 2017$0.83$0.88$9.25 billion$9.43 billionViewListenView Earnings Details
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merck & Company (NYSE:MRK)
2017 EPS Consensus Estimate: $3.69
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.85$0.85$0.85
Q2 20173$0.86$0.89$0.88
Q3 20173$1.00$1.03$1.02
Q4 20172$0.94$0.95$0.95
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Merck & Company (NYSE:MRK)

Most Recent Dividend:10/6/2017
Annual Dividend:$1.88
Dividend Yield:3.41%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:112.58% (Trailing 12 Months of Earnings)
47.59% (Based on This Year's Estimates)
45.74% (Based on Next Year's Estimates)
Track Record:5 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Merck & Company (NYSE:MRK)

Dividend History by Quarter for Merck & Company (NYSE MRK)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/25/2017quarterly$0.479/14/20179/15/201710/6/2017
5/23/2017quarterly$0.472.9%6/13/20176/15/20177/10/2017
2/28/2017quarterly$0.473/13/20173/15/20174/7/2017
11/22/2016quarterly$0.473.05%12/13/201612/15/20161/9/2017
7/26/2016quarterly$0.463.14%9/13/20169/15/201610/7/2016
5/24/2016quarterly$0.463.25%6/13/20166/15/20167/8/2016
2/23/2016quarterly$0.463.64%3/11/20163/15/20164/7/2016
11/24/2015quarterly$0.463.43%12/11/201512/15/20151/8/2016
7/22/2015quarterly$0.453.1%9/11/20159/15/201510/7/2015
5/26/2015quarterly$0.453.03%6/11/20156/15/20157/8/2015
2/24/2015quarterly$0.453.05%3/12/20153/16/20154/8/2015
11/25/2014quarterly$0.453.01%12/11/201412/15/20141/8/2015
7/23/2014quarterly$0.443.02%9/11/20149/15/201410/7/2014
5/27/2014quarterly$0.443.12%6/12/20146/16/20147/8/2014
2/25/2014quarterly$0.443.13%3/13/20143/17/20144/7/2014
11/26/2013quarterly$0.443.53%12/12/201312/16/20131/8/2014
7/24/2013quarterly$0.433.57%9/12/20139/16/201310/7/2013
5/28/2013quarterly$0.433.67%6/13/20136/17/20137/8/2013
2/26/2013quarterly$0.434%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merck & Company (NYSE MRK)

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 72.98%
Insider Trades by Quarter for Merck & Company (NYSE:MRK)
Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Insider Trades by Quarter for Merck & Company (NYSE MRK)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2017Thomas H GlocerDirectorSell5,000$56.20$281,000.00View SEC Filing  
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.00View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.00View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.00View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.00View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.46View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.00View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Merck & Company (NYSE MRK)

Source:
DateHeadline
Merck & Co., Inc. :MRK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017Merck & Co., Inc. :MRK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
finance.yahoo.com - November 18 at 5:19 AM
ETFs with exposure to Merck & Co., Inc. : November 17, 2017ETFs with exposure to Merck & Co., Inc. : November 17, 2017
finance.yahoo.com - November 18 at 5:19 AM
Merck & Co (MRK) a Sell on Falling Industry Group RankMerck & Co (MRK) a Sell on Falling Industry Group Rank
investorplace.com - November 17 at 1:11 PM
Merck & Company, Inc. (MRK) Rating Reiterated by Sanford C. BernsteinMerck & Company, Inc. (MRK) Rating Reiterated by Sanford C. Bernstein
www.americanbankingnews.com - November 16 at 1:28 PM
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis - NasdaqMerck (MRK) Gets CHMP Nod for Infection Candidate Prevymis - Nasdaq
www.nasdaq.com - November 15 at 6:28 AM
Merck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European UnionMerck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European Union
finance.yahoo.com - November 14 at 3:04 AM
Merck Announces Pricing of Any and All Tender OffersMerck Announces Pricing of Any and All Tender Offers
finance.yahoo.com - November 14 at 3:04 AM
Trump taps ex-pharma executive Azar as U.S. health secretaryTrump taps ex-pharma executive Azar as U.S. health secretary
finance.yahoo.com - November 14 at 3:04 AM
Merck & Company, Inc. (MRK) Given Consensus Recommendation of "Hold" by BrokeragesMerck & Company, Inc. (MRK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 12 at 10:38 PM
Intel, Merck Sink DJIA on FridayIntel, Merck Sink DJIA on Friday
www.msn.com - November 12 at 8:36 AM
Adverse Earnings Growth Make Merck & Co (MRK) a SellAdverse Earnings Growth Make Merck & Co (MRK) a Sell
investorplace.com - November 10 at 10:08 AM
Thomas H. Glocer Sells 5,000 Shares of Merck & Company, Inc. (MRK) StockThomas H. Glocer Sells 5,000 Shares of Merck & Company, Inc. (MRK) Stock
www.americanbankingnews.com - November 9 at 7:28 PM
Here's Why Merck & Co., Inc. Tanked 14% in OctoberHere's Why Merck & Co., Inc. Tanked 14% in October
finance.yahoo.com - November 9 at 5:51 AM
AstraZeneca Q3 sales weak as it waits for medicine to workAstraZeneca Q3 sales weak as it waits for medicine to work
finance.yahoo.com - November 9 at 5:50 AM
AstraZeneca sales decline slows as it waits for medicine to workAstraZeneca sales decline slows as it waits for medicine to work
finance.yahoo.com - November 9 at 5:50 AM
Interesting March 2018 Stock Options for MRK - NasdaqInteresting March 2018 Stock Options for MRK - Nasdaq
www.nasdaq.com - November 7 at 7:04 AM
Merck Publishes Annual Corporate Responsibility ReportMerck Publishes Annual Corporate Responsibility Report
finance.yahoo.com - November 4 at 5:47 AM
Cowen and Company Reiterates Hold Rating for Merck & Company, Inc. (MRK)Cowen and Company Reiterates Hold Rating for Merck & Company, Inc. (MRK)
www.americanbankingnews.com - November 3 at 7:50 PM
Earnings Visibility Keeps Merck & Co (MRK) a SellEarnings Visibility Keeps Merck & Co (MRK) a Sell
investorplace.com - November 3 at 9:24 AM
Jefferies Group Research Analysts Lower Earnings Estimates for Merck & Company, Inc. (MRK)Jefferies Group Research Analysts Lower Earnings Estimates for Merck & Company, Inc. (MRK)
www.americanbankingnews.com - November 2 at 3:32 PM
Todays Research Reports on Stocks to Watch: Merck & Co. and NovartisToday's Research Reports on Stocks to Watch: Merck & Co. and Novartis
finance.yahoo.com - November 2 at 6:35 AM
Big Pharma: Win Some, Lose SomeBig Pharma: Win Some, Lose Some
finance.yahoo.com - November 2 at 6:35 AM
Merck Stock Down After Pulling Keytruda in EuropeMerck Stock Down After Pulling Keytruda in Europe
finance.yahoo.com - November 2 at 6:35 AM
Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the DiseaseMerck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
finance.yahoo.com - November 2 at 6:34 AM
Q4 2017 EPS Estimates for Merck & Company, Inc. (MRK) Decreased by SunTrust BanksQ4 2017 EPS Estimates for Merck & Company, Inc. (MRK) Decreased by SunTrust Banks
www.americanbankingnews.com - November 1 at 11:40 AM
Jefferies Group Weighs in on Merck & Company, Inc.s FY2017 Earnings (MRK)Jefferies Group Weighs in on Merck & Company, Inc.'s FY2017 Earnings (MRK)
www.americanbankingnews.com - November 1 at 9:18 AM
Merck begins sale process of consumer unit - FT - Seeking AlphaMerck begins sale process of consumer unit - FT - Seeking Alpha
seekingalpha.com - November 1 at 6:26 AM
Merck begins sale process of consumer unit - FT - Seeking AlphaMerck begins sale process of consumer unit - FT - Seeking Alpha
seekingalpha.com - November 1 at 6:26 AM
Merck & Company, Inc. (MRK) to Post FY2017 Earnings of $3.94 Per Share, SunTrust Banks ForecastsMerck & Company, Inc. (MRK) to Post FY2017 Earnings of $3.94 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - October 31 at 6:48 AM
Leerink Swann Comments on Merck & Company, Inc.s FY2017 Earnings (MRK)Leerink Swann Comments on Merck & Company, Inc.'s FY2017 Earnings (MRK)
www.americanbankingnews.com - October 31 at 6:48 AM
Thinking about buying stock in Adamas Pharmaceuticals, Diamond Offshore Drilling, Merck & Company Incorporated, Pfizer Inc, or Under Armour?Thinking about buying stock in Adamas Pharmaceuticals, Diamond Offshore Drilling, Merck & Company Incorporated, Pfizer Inc, or Under Armour?
www.bizjournals.com - October 31 at 6:32 AM
Cancer-drug setback sends Merck shares down againCancer-drug setback sends Merck shares down again
finance.yahoo.com - October 31 at 6:32 AM
Merck downgraded after delaying lung cancer trial resultsMerck downgraded after delaying lung cancer trial results
finance.yahoo.com - October 31 at 6:31 AM
Merck Has Good Reasons for Its Keytruda DelayMerck Has Good Reasons for Its Keytruda Delay
finance.yahoo.com - October 31 at 6:31 AM
Merck set for sixth day of declines after pulling Europea...Merck set for sixth day of declines after pulling Europea...
finance.yahoo.com - October 31 at 6:31 AM
Mercks stock suffering biggest 2-day selloff since February 2009Merck's stock suffering biggest 2-day selloff since February 2009
finance.yahoo.com - October 31 at 6:31 AM
Head-To-Head Survey: Merck & (MRK) & The CompetitionHead-To-Head Survey: Merck & (MRK) & The Competition
www.americanbankingnews.com - October 30 at 7:40 PM
Merck & Company, Inc. (MRK) PT Lowered to $69.00 at Leerink SwannMerck & Company, Inc. (MRK) PT Lowered to $69.00 at Leerink Swann
www.americanbankingnews.com - October 30 at 4:36 PM
Merck Shares Drop in Premarket After European Keytruda Application WithdrawnMerck Shares Drop in Premarket After European Keytruda Application Withdrawn
finance.yahoo.com - October 30 at 5:53 AM
Merck Earnings Fall Short Despite Incredible Keytruda SalesMerck Earnings Fall Short Despite Incredible Keytruda Sales
247wallst.com - October 29 at 7:50 PM
3 Bright Spots in Merck's Q3 Results3 Bright Spots in Merck's Q3 Results
finance.yahoo.com - October 29 at 7:49 PM
Despite Profit Beat, Merck Shares Fall Due to Impact of NotPetya Attack - NasdaqDespite Profit Beat, Merck Shares Fall Due to Impact of NotPetya Attack - Nasdaq
www.nasdaq.com - October 28 at 8:23 AM
Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong - NasdaqMerck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong - Nasdaq
www.nasdaq.com - October 28 at 8:23 AM
Merck & Co., Inc. (MRK) Takes a Hit After Q3 Loss | InvestorPlace - Investorplace.comMerck & Co., Inc. (MRK) Takes a Hit After Q3 Loss | InvestorPlace - Investorplace.com
investorplace.com - October 28 at 8:23 AM
Merck & Co., Inc. (MRK) Takes a Hit After Q3 LossMerck & Co., Inc. (MRK) Takes a Hit After Q3 Loss
finance.yahoo.com - October 28 at 8:23 AM
Edited Transcript of MRK earnings conference call or presentation 27-Oct-17 12:00pm GMTEdited Transcript of MRK earnings conference call or presentation 27-Oct-17 12:00pm GMT
finance.yahoo.com - October 28 at 8:23 AM
[$$] Merck Swings to Loss as Cyberattack Hurts Sales[$$] Merck Swings to Loss as Cyberattack Hurts Sales
finance.yahoo.com - October 28 at 8:23 AM
Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - October 28 at 8:23 AM
Merck pulls European application for lung cancer drugMerck pulls European application for lung cancer drug
finance.yahoo.com - October 28 at 8:23 AM
Merck withdraws marketing application for Keytruda in EuropeMerck withdraws marketing application for Keytruda in Europe
finance.yahoo.com - October 28 at 8:23 AM

Social Media

Financials

Chart

Merck & Company (NYSE MRK) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.